Vorasidenib

**Cat. No.:** HY-104042  
**CAS No.:** 1644545-52-7  
**Molecular Formula:** C₁₄H₁₃ClF₆N₆  
**Molecular Weight:** 414.74  
**Target:** Isocitrate Dehydrogenase (IDH)  
**Pathway:** Metabolic Enzyme/Protease  

**Storage:**  
- Powder: -20°C 3 years, 4°C 2 years  
- In solvent: -80°C 6 months, -20°C 1 month

---

**SOLVENT & SOLUBILITY**

**In Vitro**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.4111 mL</td>
<td>12.0557 mL</td>
<td>24.1115 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4822 mL</td>
<td>2.4111 mL</td>
<td>4.8223 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2411 mL</td>
<td>1.2056 mL</td>
<td>2.4111 mL</td>
<td></td>
</tr>
</tbody>
</table>

DMSO: 100 mg/mL (241.11 mM; Need ultrasonic)

**Preparing Stock Solutions**

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
   Solubility: 2.08 mg/mL (5.02 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
   Solubility: 2.08 mg/mL (5.02 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil  
   Solubility: 2.08 mg/mL (5.02 mM); Clear solution; Need warming
4. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline  
   Solubility: 2.5 mg/mL (6.03 mM); Suspended solution; Need ultrasonic
5. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)  
   Solubility: 2.4 mg/mL (5.79 mM); Suspended solution; Need ultrasonic

---

**BIOLOGICAL ACTIVITY**

**Description**

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC₅₀ ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and
IC₅₀ & Target

<table>
<thead>
<tr>
<th>Target</th>
<th>IC₅₀</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDH1 R132C</td>
<td>0.04–22 nM</td>
<td>[1],[2]</td>
</tr>
<tr>
<td>IDH1 R132G, IDH1 R132H, IDH1 R132S</td>
<td>7–14 nM</td>
<td>[2]</td>
</tr>
<tr>
<td>IDH2 R140Q</td>
<td>130 nM</td>
<td>[2]</td>
</tr>
</tbody>
</table>

In Vitro

Vorasidenib has strong antiproliferative activity against human glioblastoma U-87 MG pLVX-IDH2 R140Q-neo, fibrosarcoma HT-1080 and neurosphere TS603 cells, all with IC₅₀s of less than 50 nM[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION


See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

REFERENCES
